Thesis
Effect of bupivacaine concentration and formulation on canine chondrocyte viability in vitro
Washington State University
Master of Science (MS), Washington State University
05/2021
DOI:
https://doi.org/10.7273/000000090
Handle:
https://hdl.handle.net/2376/111799
Abstract
Objective: To quantitate bupivacaine concentration and formulation effects on chondrocyte
viability in vitro.
Methods: Cell passage 3 and 4 primary canine chondrocyte isolates were exposed to 0.9%
saline; canine chondrocyte growth medium; 0.4, 0.5, 0.6, 1.5, 2.5, 3.5, or 5 mg/ mL preservativefree standard formulation bupivacaine; or 13.3 or 6.65 mg/mL liposomal encapsulated
bupivacaine for 1 hour. Chondrocyte viability and clonogenicity were quantitated with 3-(4,5-
dimethylthiazol-2-31 yl)-2,5-diphenyltetrazolium bromide (MTT) and clonogenic assays,
respectively. Differences among concentrations and formulations were assessed with KruskalWallis and Dwass-Steel-Critchlow-Fligner post hoc tests.
Results: Growth medium had the highest cell viability based on MTT metabolism assay.
Similarly, all liposomal encapsulated bupivacaine concentration groups had higher cell viability
compared with standard formulation bupivacaine concentration cells treated with 3.5 or 5 mg/mL
standard formulation bupivacaine (P < .03). Among standard formulation concentrations, cell
viability was higher at 0.6 mg/mL compared with at 2.5 mg/mL or greater (P < .03). Cell clonogenicity was not significantly different between saline, culture medium, or 0.5 mg/mL
standard formulation bupivacaine. Clonogenicity was lower with all tested liposomal
encapsulated bupivacaine concentrations compared with saline or growth medium (P < .02).
Conclusion: In vitro toxicity of standard formulation bupivacaine on canine chondrocytes is
concentration dependent. Liposomal encapsulated bupivacaine may have time-dependent effects
resulting in chondrotoxicity.
Clinical significance: Clinically relevant concentrations of standard formulation bupivacaine
after a single injection may not result in chondrotoxic effects in vitro. Liposomal encapsulated
bupivacaine should not be used in the articular environment.
Metrics
6 File views/ downloads
28 Record Views
Details
- Title
- Effect of bupivacaine concentration and formulation on canine chondrocyte viability in vitro
- Creators
- Roger Rengert
- Contributors
- STEVEN A MARTINEZ (Degree Supervisor) - Washington State University, Veterinary Clinical Sciences, Department ofPETER J GILBERT (Committee Member) - Washington State University, Veterinary Clinical Sciences, Department ofTINA JO OWEN (Committee Member) - Washington State University, Veterinary Clinical Sciences, Department of
- Awarding Institution
- Washington State University
- Academic Unit
- Veterinary Medicine, College of
- Theses and Dissertations
- Master of Science (MS), Washington State University
- Publisher
- Washington State University
- Format
- pdf
- Number of pages
- 27
- Identifiers
- 99900587063301842
- Language
- English
- Resource Type
- Thesis